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OR I G I N A L R E S E A R C H
Targeting Prostate Cancer Using Intratumoral
Cytotopically Modified Interleukin-15
Immunotherapy in a Syngeneic Murine Model
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Background: The prostate cancer microenvironment is highly immunosuppressive; immune
cells stimulated in the periphery by systemic immunotherapies will be rendered inactive once
entering this environment. Immunotherapies for prostate cancer need to break this immune
tolerance. We have previously identified interleukin-15 (IL-15) as the only cytokine tested
that activates and expands immune cells in the presence of prostate cancer cells. In the
current study, we aimed to identify a method of boosting the efficacy of IL-15 in prostate
cancer.
Methods: We engineered, by conjugation to a myristoylated peptide, a membrane-localis-
ing form of IL-15 (cyto-IL-15) and the checkpoint inhibitor antibodies cytotoxic T lym-
phocyte antigen 4 (CTLA-4) and programmed death ligand 1 (PD-L1) (cyto-abs) to enable
them to bind to cell surfaces by non-specific anchoring to the phospholipid bilayer. The
efficacy of these agents was investigated by intratumoral administration either alone (cyto-
IL-15 or cyto-abs) or in combination (cyto-combo) in subcutaneous TRAMP-C2 prostate
tumors in C57BL/6J mice and compared with their non-modified equivalents in vivo.
Following the survival endpoint, histological analyses and RNA sequencing were per-
formed on the tumors.
Results: Intratumoral injection of cyto-IL-15 or cyto-combo delayed tumor growth by 50%
and increased median survival to 28 and 25 days, respectively, compared with vehicle (17
days), whereas non-modified IL-15 or antibodies alone had no significant effects on tumor
growth or survival. Histological analysis showed that cyto-IL-15 and cyto-combo increased
necrosis and infiltration of natural killer (NK) cells and CD8 T cells in the tumors compared
with vehicle and non-modified agents. Overall, the efficacy of cyto-combo was not superior
to that of cyto-IL-15 alone.
Conclusion: We have demonstrated that intratumoral injection of cyto-IL-15 leads to
prostate cancer growth delay, induces tumor necrosis and increases survival. Hence, cyto-
topic modification in combination with intratumoral injection appears to be a promising
novel approach for prostate cancer immunotherapy.
Keywords: IL-15, checkpoint blockade, prostate cancer, cytotopic modification, NK cells
Key Points
Membrane-localising IL-15, injected directly into prostate tumors in mice induces tumor
death and improves mouse survival while circumventing toxicities seen with cytokine
immunotherapies administered systemically. This modified IL-15 could have a great impact
in treating prostate cancer patients.
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Introduction
Prostate cancer is the second leading cause of cancer-
related death behind lung cancer, and the most common
malignancy diagnosed in men.1 Treatments for prostate
cancer include surgery, radiation, chemotherapy and
androgen deprivation therapy. However, despite the high
rates of progression-free survival, almost half of the
patients progress to castration-resistant prostate cancer
(CRPC).2
It has previously been suggested that prostate cancer
can be immunogenic. This is supported by the presence of
numerous tumor-associated antigens in the prostate,
including prostate-specific antigen (PSA) and prostatic
acid phosphatase (PAP), as well as tumor infiltrating lym-
phocytes (TILs), such as CD4 and CD8 T cells, natural
killer (NK) cells, dendritic cells (DCs) and macrophages
within tumors.3–5 However, the prostate cancer immuno-
genicity is hampered by the highly immunosuppressive
microenvironment, which is probably due to improper
functionality of TILs (anergy, exhaustion or senescence)
or the presence of regulatory T cells (Tregs).6 High-grade
prostate cancer with poorer prognosis has low infiltration
of T cells and DCs and high occurrence of Tregs and
tumor-associated macrophages;7–9 whereas, elevated infil-
tration of NK cells within tumors is associated with low
risk of prostate cancer progression.10 Immunotherapy,
which aims to overcome the immunosuppressive micro-
environment and generate or enhance immune responses
against tumor cells, has emerged as a promising alternative
therapeutic approach for the treatment of prostate cancer.
Immunotherapies fall into four categories: adoptive T
cell therapy, cancer vaccines, checkpoint inhibitors and
cytokines.11 The only FDA-approved vaccine for prostate
cancer is Sipuleucel-T (Provenge®), a DC-based vaccine
that activates an antitumor response against PAP.12
However, Sipuleucel-T only extends patient survival by
few months.13 One of the most studied immune checkpoint
targets is cytotoxic T lymphocyte antigen 4 (CTLA-4),
which downregulates T cell activation. The anti-CTLA-4
blocking antibody ipilimumab is FDA-approved for the
treatment of advanced melanoma and is undergoing clinical
trials for prostate cancer. So far, ipilimumab showed no
benefit in overall survival, but it slightly improved progres-
sion-free survival in metastatic CRPC.14 Programmed cell
death protein 1 (PD-1) and programmed death ligand 1 (PD-
L1) are also checkpoint targets as their interaction (PD-1/
PD-L1) mediates immunosuppression, and thus is a crucial
mechanism by which tumors escape immune response.15 To
date, the FDA has approved at least six antibodies targeting
PD-1/PD-L1, for the treatment of patients with melanoma
and solid tumors, such as non-small cell lung cancer and
urothelial cancer.16 The anti-PD-1 antibody pembrolizumab
is FDA-approved for metastatic melanoma and solid tumors
with mismatch repair deficiency or microsatellite instabil-
ity, including metastatic CRPC, for which it has shown a
favourable side effect profile.17 However, immunotherapy
in prostate cancer has shown less efficacy than in other
tumors, probably due to the low somatic mutation burden
and suppressive tumor microenvironment.18–20 Therefore,
immunotherapies that lead to activation and proliferation of
NK and T cells within the tumor microenvironment, used
alone or combined with other types of immunotherapies,
may prove to be more efficacious than those aimed at a
single target.
One of the most promising cytokines for cancer immu-
notherapy is interleukin-15 (IL-15), which has several biolo-
gical functions equivalent to those of interleukin-2 (IL-2) –
another known cytokine used for cancer immunotherapy –
but without any significant sequence homology. IL-15 med-
iates its functions through the IL-2/IL-15Rβ-chain and com-
mon gamma (γc)-chain that it shares with the IL-2 receptor,
and its own unique IL-15Rα-chain.21,22 Similar functions of
IL-15 and IL-2 are: stimulation of T cell proliferation, gen-
eration of cytotoxic T lymphocytes (CTLs), stimulation of
immunoglobulin synthesis by B cells, and proliferation and
activation of NK cells.23,24 IL-2 and IL-15 have also distinct
functions crucial for maintaining homeostasis of adaptive
immune responses. IL-2 inhibits T cell responses by elim-
inating self-reactive T cells through activation-induced cell
death (AICD) of CD8 effector T cells, and is involved in the
maintenance and retention of Tregs.25,26 In contrast, IL-15
has a role in T and NK cell activation, in the survival of CD8
memory T cells, in inhibiting AICD, while it has no effect on
Tregs. Those distinct functions of IL-15 make it a more
suitable cytokine for cancer immunotherapy.21,27,28
We have recently shown that IL-15 is the only cytokine
among a panel of agents that can expand and activate
immune cells and that the presence of prostate cancer cells
augments its capability.29 Moreover, a study in a TRAMP-
C2 prostate tumor model showed that IL-15 combined with
anti-CTLA-4 and anti-PD-L1 antibodies decreased tumor
growth and prolong survival of tumor-bearing animals.30
Other preclinical studies have shown that IL-15 treatment
leads to less toxicities with limited vascular capillary leak
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compared to IL-2,31 while the T cell-mediated antitumor
potency of IL-15 is greater than that of IL-2.32
In the present study, the immunotherapeutic potential of
IL-15 was explored as monotherapy or in combination with
two checkpoint inhibitor antibodies, CTLA-4 and PD-L1,
administered intratumorally in prostate cancer. To enhance
and prolong the therapeutic capabilities of IL-15, anti-
CTLA-4 and anti-PD-L1 antibodies, we created novel cyto-
topic (membrane-localising) forms of these agents that can
adhere to cell surfaces by non-specific anchoring to the
phospholipid bilayer, while maintaining the ability to recog-
nise and bind to their receptors. Initially, the binding effi-
ciency and the activity of these proteins were investigated in
vitro. The efficacy of the agents was then explored in a
syngeneic subcutaneous prostate cancer mouse model and
tumor response was characterized using histopathology,
cytokine analysis and RNA sequencing on tumor extracts.
Methods
Cytotopic Modifications of Proteins
The doubly myristoylated peptide (2.36 kDa) (named
PTL3146) consisted of two fatty acid myristoyl chains
attached to the N-terminus of the L-lysine residue, a posi-
tively charged peptide and an activated thiol group;33
sequence provided in Figure S1 (Supplementary File).
The myristoyl chains insert spontaneously into the phos-
pholipid bilayer upon interaction with cell surfaces, the
peptide interacts with the negatively charged membrane,
and the thiol group forms a disulphide bridge with the free
cysteine within the protein of interest.
IL-15: Recombinant IL-15 containing the full human IL-15
sequence and a C-terminus linker with a free cysteine (total
molecular mass of 17.68 kDa) was expressed in E.coli and
purified by GenScript Corporation (New Jersey, USA);
sequence provided in Figure S1 (Supplementary File). For
the cytotopic modification, IL-15 was partially reduced at the
C-terminus with tris(2-carboxyethyl)phosphine (TCEP)
(ThermoFisher) at a final concentration of 300µM for 1 h.
The excess of reducing agent was removed using a G-25 spin
column (GEHealthcare, Little Chalfont, UK). The reduced IL-
15 was then incubated with the PTL3146 peptide (10mM in
DMSO) at a 1:3 protein to peptide molar ratio at room tem-
perature (RT) for 60 to 90 min and subsequently at 4°C over-
night. The unbound PTL3146was removedwith dialysis using
a Spectra-Por Micro float-A-Lyzer device (Sigma-Aldrich,
Dorset, UK) against phosphate-buffered saline (PBS) (Severn
Biotech Ltd., Kidderminster, UK). The cytotopically-modified
IL-15was termed cyto-IL-15 in the present study and currently
a patent has been filed (application number GB 1,913,804.9)
with the name Haptoleukin-15.
Anti-PD-L1 and anti-CTLA-4 antibodies: Rat monoclo-
nal anti-mouse PD-L1 (B7-H1) antibody (10F.9G2,
BioXcell, West Lebanon, USA) and Armenian hamster
monoclonal anti-mouse CTLA-4 (CD152) antibody
(UC10-4F10-11, BioXcell) were cytotopically modified
by applying a method using 2-iminothiolane.34 Briefly, the
antibody (either anti-PD-L1 or anti-CTLA-4) was incu-
bated with a 100 mM freshly prepared solution of 2-imi-
nothiolane hydrochloride (2-IT.HCl) (Sigma-Aldrich) for
30 min at RT (all solutions used were degassed). Then, the
PTL3146 peptide (10mM in DMSO) was added (1:3 protein
to peptide molar ratio) and the reaction was monitored by
measuring the absorbance of pyridine-2-thione (reaction
by-product) at 343 nm. The reaction was continued until
one to two molecules of peptide were attached to each
antibody molecule. The modified antibody was purified
using a G-25 spin column to remove residual 2-IT.HCl
and peptide. The cytotopically modified antibodies (abs)
were termed cyto-PD-L1 and cyto-CTLA-4 (cyto-abs).
Concentration of the cytotopically-modified proteins
was determined using a Pierce BCA protein assay Kit
(ThermoFisher) according to manufacturer’s instructions.
Cyto-IL-15 concentration was also measured using a human
IL-15 ELISA MAX (Biolegend, London, UK) according to
manufacturer’s instructions.
Cell Culture
Transgenic adenocarcinoma of the mouse prostate (TRAMP)-
C2 cells, obtained from American Type Culture Collection
(ATCC, Teddington, UK), were maintained in Dulbecco’s
Modified Eagle’s culture medium (DMEM) supplemented
with 2mM L-glutamine, 1% antibiotic antimycotic solution,
0.2% gentamicin, 100 U/mL penicillin, 0.2 mg/mL streptomy-
cin, 5 µg/mL insulin, 0.01 nM dihydrotestosterone (all from
Sigma-Aldrich), 5% fetal bovine serum (FBS) (Life
Technologies, Paisley, UK) and 5% NuSerum IV culture
supplement (ThermoFisher Scientific, Dartford, UK).
Human peripheral blood mononuclear cells (PBMCs) were
maintained in RPMI-1640 medium supplemented with 2mM
L-glutamine, 1% antibiotic antimycotic solution, 0.2% genta-
micin and 10% FBS (referred to as RPMI complete medium).
The PBMCs isolation method is described in Supplementary
Methods (Supplementary File). Murine cytotoxic T lympho-
cyte CTLL-2 cells, obtained from European Collection of
Authenticated Cell Cultures, were maintained in RPMI
Dovepress Papaevangelou et al
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complete medium supplemented with 10% T-STIM culture
supplement with Concanavalin A (ThermoFisher). Human T
lymphocyte Jurkat cells (ATCC) were maintained in RPMI
complete medium. Murine T lymphocyte EL4 cells (ATCC)
were maintained in DMEM supplemented with 2mM L-gluta-
mine, 1% antibiotic antimycotic solution, 0.2% gentamicin
and 10% FBS. Cells were kept in a humidified atmosphere
with 5% CO2 at 37°C and were negative for mycoplasma
infection, which was tested every few months (approximately
10 passages) using LookOut Mycoplasma PCR (Sigma-
Aldrich). Cell lines were used within 2 years from the date
of purchase.
Cell Proliferation Assay
The activity of IL-15 was investigated using a CTLL-2 cell
proliferation assay. CTLL-2 cells were incubated for 4 hours
in phenol-free RPMI complete medium without T-STIM.
Subsequently, 3.5x104 cells/well were seeded in 96-well
plates and treated with IL-15 (Genscript) or cytotopically-
modified IL-15 at a range of 0–1.6 ng/mL concentration.
Commercial IL-15, which is recombinant human IL-15
(without a C-terminus linker) was purchased from
PeproTech EC Ltd. (London, UK) and used as control.
After 3 days, cells were incubated with CellTiter 96
AQueous One Solution reagent (Promega, Southampton,
UK) in the dark at 37°C for up to 4 hours. The reaction was
stopped with 10% SDS and the absorbance was measured at
490 nm using a Hidex Sense microplate reader (LabLogic
Systems Ltd, Sheffield, UK). Background absorbance was
measured in wells with medium only.
Animals and Tumors
Animal experiments were performed in accordance with the
local ethical review panel and the UK Home Office Animals
(Scientific Procedures) Act 1986. Male C57BL/6J mice, 6–8
weeks old (Charles River, Harlow, UK), were injectedwith 5 x
106 TRAMP-C2 cells in 0.1 mL PBS subcutaneously into the
right flank. The tumor length (L), width (W) and depth (D)
were measured using callipers and the volume was calculated
using the ellipsoid shape formula: (π/6) x L x W x D. When
tumors were palpable and well established with an approxi-
mate volume of 100 mm3, mice were randomly divided into
eight treatment cohorts. Mice in each cohort where treated
intratumorally with vehicle (PBS, n = 13), 10 μg/dose IL-15 or
cyto-IL-15 (n = 10, each), 100 μg/dose of each of the abs or
each of the cyto-abs (n = 6, each), combination of IL-15 and
abs (combo) or combination of cyto-IL-15 and cyto-abs (cyto-
combo) (n = 10, each). The last cohort was treated with 10 µg/
dose IL-15 intraperitoneally (IL-15 i.p., n = 6). IL-15 was
given at two doses injected at days 0 and 3, while antibodies
were injected as a single dose at day 0. Day 3 was chosen in
order to mitigate any potential injection-related adverse
effects. Mice were monitored for weight loss, hunched pos-
ture, discomfort and development of rashes. When tumors
reached a maximum diameter of 15 mm (survival endpoint)
they were excised and snap frozen.
Histology and Immunofluorescence
Frozen tumor sections (8 µm thick) were cut axially from two
regions for each tumor, one in the centre of the tumor and one
1 mm apart. To assess immune cell infiltration, acetone-fixed
sections were stained with a rabbit monoclonal anti-CD4
antibody [EPR19514] (1/200, Abcam, Cambridge, UK) and
Alexa Fluor 546 goat anti-rabbit secondary antibody (3/1000,
ThermoFisher), and a rat monoclonal anti-CD8 antibody
[YTS169.4] (1/100, Abcam) and Alexa Fluor 488 donkey
anti-rat secondary antibody (1.5/1000, ThermoFisher).
Sections were also stained with a rabbit monoclonal anti-
CD3 antibody [SP7] (1/100, Abcam) and Alexa Fluor 546
goat anti-rabbit secondary antibody, and Alexa Fluor 488-
conjugatedmousemonoclonal anti-NK1.1 antibody [PK136]
(1/25, BioLegend). Non-immune-specific immunoglobulins
(same classes and concentrations as the primary antibodies)
were used as negative isotype controls, whereas mouse
spleens were used as positive controls. Fluorescent staining
was visualised under a BX51 microscope (Olympus Optical,
London, UK) using a QImaging camera (Cairn Research,
Faversham, UK). For each tumor (n = 5 per treatment
cohort), images were acquired from five randomly selected
areas for each of the two tumor sections for each antibody.
To quantify the degree of necrosis, sections were stained
with haematoxylin and eosin (H&E) and images were
acquired using a bright-field Hamamatsu NanoZoomer
2.0RS digital slide scanner (Hamamatsu Photonics,
Hamamatsu City, Japan). Tumor necrotic areas and fluorescent
areas for each stain were defined and analysed using ImageJ
software35 as previously described.36 Necrosis was expressed
as a percentage of the whole tumor section area, while fluor-
escent staining as a percentage of the total image area.
RNA Sequencing
Tumors treated with vehicle, IL-15 or cyto-IL-15 (n = 3/
group) were used for RNA sequencing. Tumors were disso-
ciated using a gentleMACS Dissociator according to manu-
facturer’s instructions and RNA was extracted using an
RNeasy Mini Kit (Qiagen, Manchester, UK). RNA library
Papaevangelou et al Dovepress
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preparations, sequencing reactions and bioinformatics ana-
lyses were conducted at Genewiz, LLC (New Jersey, USA).
The method is described in detail in Supplementary Methods
(Supplementary File).
Statistical Analysis
Data were analysed using GraphPad Prism 8 (GraphPad
Software, La Jolla, CA). Statistical significance of differ-
ences was determined by one- or two-way ANOVA with
Sidak’s or Dunnett’s multiple comparisons post-tests, with
a 5% level of significance. Results are presented as mean ±1
standard error of the mean (SEM). For the RNA sequencing,
the Wald test was used to generate p-values and Log2 fold
changes. Genes with adjusted p-values <0.05 and absolute
log2 fold changes >1 were defined as differentially expressed




The cytotopically-modified IL-15 was detected withWestern
blot analysis using an anti-IL-15 antibody. To confirm the
presence of the PTL3146 peptide, IL-15 and antibodies were
also modified using a FAM-labelled peptide, which could be
visualised under UV light (Supplementary Methods,
Supplementary File). Figure S2A (Supplementary File)
shows an increase in the molecular mass of IL-15 from 18
to 20 kDa after the modification. Cyto-IL-15 is also detected
after Silver staining (20 kDa), whereas the FAM-labelled
peptide is visual under UV light (Figure S2B). The FAM-
labelled peptide is also successfully bound to CTLA-4 and
PD-L1 antibodies (Figure S2C).
To investigate the ability of the cytotopically-modified
proteins to bind to cell membranes via the peptide and not
via a receptor, cells that do not express the relevant recep-
tors were used; red blood cells (RBCs) for IL-15 and naïve
Jurkat cells for CTLA-4 and PD-L1. The cell-binding
assay is described in Supplementary File (Supplementary
Methods, Cell binding assay). RBCs incubated with non-
modified IL-15 showed very low fluorescent intensity
staining the same as the control where no protein was
added. On the contrary, incubation of the cells with cyto-
IL-15 led to a significant increase in fluorescent intensity
(Figure 1A). To investigate whether the binding via the
peptide was maintained over time, after excess or unbound
protein has been removed, naïve Jurkat cells were incu-
bated with IL-15 or cyto-IL-15 and binding was measured
after 30 min or 24 h as described in Supplementary File
(Supplementary Methods, Cell binding assay). Binding of
cyto-IL-15 was maintained even after 24 h (increased
fluorescent intensity compared with control), whereas no
binding was seen with non-modified IL-15 (Figure S3,
Supplementary File). Similarly, the modified antibodies
cyto-CTLA-4 and cyto-PD-L1 increased fluorescent inten-
sity staining after incubation with naïve Jurkat cells,
whereas no shift in intensity was seen when cells were
incubated with non-modified antibodies (Figure 1A).
The activity of IL-15 after modification was investi-
gated measuring CTLL-2 cell proliferation. The non-mod-
ified and modified versions of IL-15 led to similar cell
proliferation at lower doses; however, at higher doses (1.6
ng/mL), there was significantly more proliferation with
cyto-IL-15 (p <0.001). Both IL-15 and cyto-IL-15 led to
significantly higher CTLL-2 proliferation than commercial
IL-15 (p <0.01, Figure 1B). The activity of IL-15 was also
assessed in non-adherent PBMCs as described in
Supplementary Methods (Cell expansion assay) and
Table S1 (Supplementary File). The flow cytometry gating
strategy is shown in Figure S4A (Supplementary File). NK
cell expansion was significantly increased when cells were
incubated with cyto-IL-15. More specifically, a 3.7-fold
increase was seen at 10 ng/mL and a 4.2-fold increase at
20 ng/mL compared with control (p <0.05). Non-modified
IL-15 at the same concentrations also increased NK cell
expansion by approximately 2-fold compared with control
but the result did not reach statistical significance
(Figure 1E). A small increase in the expansion of CD8
cells (1.2-fold) was also seen in PBMCs incubated with 20
ng/mL cyto-IL15 compared with control (p <0.05,
Figure 1F).
The activity of CTLA-4 antibody after modification was
assessed bymeasuring IL-2 secretion in activated Jurkat cells
as described in Supplementary Methods (CTLA-4 activity
assay, Supplementary File). CTLA-4/Fc protein inhibited
activation of Jurkat cells by binding to B7-1, and hence
inhibited IL-2 secretion by ~86%. Addition of CTLA-4 or
cyto-CTLA-4 antibodies, at concentration higher than 12.5
µg/mL, significantly restored IL-2 secretion to approxi-
mately 40% via CTLA-4/Fc protein blockade (p <0.01,
Figure 1C). The activity of PD-L1 antibody after modifica-
tion was accessed by measuring PD-1 expression in EL4
cells as described in Supplementary Methods (PD-L1 activ-
ity assay, Supplementary File). PD-L1/Fc protein blocked
PD-1 leading to reduced fluorescent staining of ~30%,
whereas addition of 200 µg/mL cyto-PD-L1 antibody
Dovepress Papaevangelou et al
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significantly restored staining to 95% via PD-L1/Fc protein
blockade (p <0.05, Figure 1D).
Immunotherapy with Cytotopically-
Modified IL-15 Causes Significant Prostate
Tumor Growth Delay
Mice with TRAMP-C2 prostate subcutaneous tumors were
injected intratumorally with non-modified or cytotopically-
modified versions of IL-15, CTLA-4 and PD-L1 antibodies.
Human IL-15 was used for treatment as the human and
mouse IL-15 genes have approximately 73% sequence
homology.37 The mean tumor volume at treatment onset
(day 0) was 106 ± 7 mm3 across all tumors. Both cyto-IL-
15 and cyto-combo treatments significantly reduced tumor
growth in comparison with vehicle by 52 (p <0.01) and 58%
(p <0.001) respectively, at day 14 post-treatment.
Combination of IL-15 and antibodies in their non-modified
forms also caused a growth delay by 48% compared with
vehicle at day 14 (p <0.01). However, neither intraperito-
neal nor intratumoral injection of non-modified IL-15 led to
significant changes in tumor growth. Similarly, treatment
with antibodies or modified antibodies did not delay growth






Figure 1 In vitro characterization of cytotopically-modified proteins. (A) Cell membrane binding of cytotopically-modified IL-15 on RBCs, and cytotopically-modified CTLA-
4 or PD-L1 antibodies on naïve Jurkat cells, detected by flow cytometric analysis using fluorescent-labelled antibodies to these proteins. (B) Proliferation of CTLL-2 cells
treated with different forms of IL-15 (n = 3 independent experiments performed in quadruplicates). Results are means ±1 SEM (*cyto-IL-15 versus commercial IL-15 or cyto-
IL-15 versus IL-15, #IL-15 versus commercial IL-15, *p <0.05, **or ##p <0.01, ***or ###p <0.001 two-way ANOVA with Tukey multiple comparisons post-test). (C) IL-2
secretion by activated Jurkat cells inhibited with CTLA-4/Fc protein and reconstituted with varying concentrations of CTLA-4 or cyto-CTLA-4 antibodies. Results are
expressed relative to IL-2 secretion by activated control cells (n = 4). (D) PD-1 binding in EL4 cells inhibited with PD-L1/Fc protein and reconstituted with varying
concentrations of PD-L1 or cyto-PD-L1 antibodies. Results are expressed relative to PD-1 expression in control cells (n = 4). (E, F) NK and CD8 T cell expansion in a
human non-adherent PBMC population treated with varying concentrations of IL-2, IL-15 or cyto-IL-15 (n = 3). (C–F) Results are means +1 SEM (*p <0.05, **p <0.01, ***p
<0.001 one-way ANOVA with Sidak’s multiple comparisons post-test).
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and cyto-combo led to a significant growth delay in com-
parison with vehicle of 37 (p <0.05), 37 (p <0.05) and 46%
(p <0.01) respectively. A significant delay in growth was
also seen with cyto-abs at day 17 by 57% compared with
vehicle (p <0.01, Figure 2A). Non-modified antibodies,
cyto-IL-15 and cyto-combo were the only treatments that
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Figure 2 Effect of modified IL-15 and antibodies on growth of TRAMP-C2 subcutaneous prostate tumors. (A) Tumor volumes up to day 17 post-treatment. Data are means + 1
SEM for all the tumors per group and comparisons are relative to vehicle (*p <0.05, **p <0.01, ***p <0.001 two-way ANOVA with Dunnett’s multiple comparisons post-test).
(B) Survival curves of mice post-treatment (*p <0.05, **p <0.01, comparisons of equality of two survival curves using Log-rank (Mantel-Cox) test). Table shows the median
survival of each group.
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significantly increased median survival to 27 (p <0.05), 28
(p <0.01) and 25 days (p <0.01) respectively, compared
with vehicle (17 days) (Figure 2B). Moreover, the combina-
tion of cytotopically-modified IL-15 and antibodies
increased survival significantly (p <0.05) compared with
the non-modified agent combination. All treatments were
well tolerated and none of the mice suffered any side
effects, such as rashes or weight loss. Moreover, no injec-
tion-related adverse effects were observed and no mice died
as a result of any of the treatments.
Cytokine Concentration in Tumors
Treated with Immunotherapeutic Agents
Release of cytokines in tumors was measured using a cytokine
bead array assay in tumor homogenates as described in
Supplementary Methods (Cytokine bead array assay,
Supplementary File). In tumors injected with cyto-combo,
the release of CCL2 was significantly decreased by approxi-
mately 4-fold (p <0.05), whereas IL-1β production was
increased by more than 2-fold compared with vehicle (p
<0.05) (Figure 3A and B). Release of GM-CSF, IL-10 and
IFN-α was significantly increased in tumors injected with
combination by 4.2- (p <0.01), 5.4- (p <0.05) and 2.9-fold
(p <0.05), respectively, compared with vehicle (Figure 3C–E).
No significant differences were observed in the release of the
rest of the cytokines measured, such as IFN-γ, TNF-α,
CXCL1, CCL5, IL-6 and CXCL10, whereas IL-2 and IFN-β
levels of production were not detectable (data not shown).
Moreover, intratumoral treatment with antibodies or cyto-
abs, or treatment with IL-15 intraperitoneally had no effect
on cytokine release in the tumors (data not shown).
To detect whether any of the injected IL-15 or cyto-IL15
was retained and transferred to blood circulation, the con-
centration of IL-15 was measured in the mouse blood plasma
collected from treated mice at the survival endpoint using an
IL-15 ELISA. IL-15 levels were mostly not detectable, with
concentration ranging from 0 to 7 pg/mL, and no significant
differences were observed between treatment cohorts
(Figure S5A, Supplementary File).
Treatment with Cyto-IL-15 and Cyto-
Combo Induced Tumor Necrosis and
Increased Immune Cell Infiltration
Figure 4 shows representative histological sections of excised
tumors at survival endpoints after treatment with vehicle, IL-
15, cyto-IL15, combo and cyto-combo stained with H&E
(Figure 4A), CD4 and CD8 antibodies (Figure 4B), and CD3
and NK1.1 antibodies (Figure 4C). Most NK and CD8 T cells
were observed close to or inside necrotic regions. Moreover,
areas with NK cells mainly lacked CD3 cells. This is more
clearly depicted in Figure S6 (Supplementary File), where two




Figure 3 Assessment of cytokines in TRAMP-C2 prostate tumor homogenates. CCL2 (A), IL-1β (B), GM-CSF (C), IL-10 (D) and IFN-α (E) concentration in tumor
homogenates derived from tumors treated with vehicle, IL-15, cyto-IL15, combo or cyto-combo. Results are means +1 SEM of duplicate measurements made from all
tumors in each cohort (n = 10) corrected for protein concentration. Comparisons are relative to vehicle (*p <0.05, **p <0.01, one-way ANOVA with Dunnett’s multiple
comparisons post-test).
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are shown, one has mostly CD3 cells (left) and the other
mostly NK cells (right).
Quantification of tumor necrosis using the H&E stained
sections is shown in Figure 5A. Cyto-IL15, combo and cyto-
combo caused a significantly higher and increasing degree of
necrosis (32 ± 6% (p <0.05), 34 ± 9% (p <0.01), and 43 ± 8%
(p <0.0001), respectively) compared with vehicle (20± 8%).
CD4 staining was also increased in these treatment cohorts
(1.5% (p<0.0001) for cyto-IL-15, 1% (p<0.01) for combo and
1.6% (p <0.0001) for cyto-combo) compared with 0.6% in the
vehicle (Figure 5B). However, CD8 and NK1.1 staining were
only increased in the cohorts receiving modified IL-15 or
combination of modified immunotherapies; 0.13% (p
<0.001) for cyto-IL-15 and 0.11% (p <0.01) for cyto-combo
compared with 0.05% in vehicle for CD8, and 0.50% (p
<0.0001) for cyto-IL-15 and 0.44% (p <0.001) for cyto-
combo compared with 0.10% in vehicle for NK1.1
(Figure 5C and E). Moreover, all the above markers (necrosis,
CD4, CD8 and NK1.1) were significantly higher in tumors
treatedwith cytotopically-modified agents comparedwith their
non-modified versions (cyto-IL-15 versus IL-15 and cyto-
combo versus combo). CD3 staining was slightly decreased
in the cyto-IL-15 and cyto-combo groups compared with the
other cohorts, but this was not statistically significant
(Figure 5D).
To investigate whether the increase of NK and CD8 T
cells observed in the tumors was due to increased production
of these cells in the spleen, splenocytes were isolated from
mouse spleens collected at survival endpoints from treated
mice, stimulated, and flow cytometry analysis was performed
(Supplementary Methods: Splenocyte ex vivo stimulation,
Figure S4B, and Table S1, Supplementary File). NK cell
number significantly increased by almost 2-fold (p <0.05)
in the cyto-IL-15 cohort compared with vehicle (Figure S5B,
Supplementary File), whereas no significant differences were
measured in the numbers of CD8 T cells (data not shown).
m100 







Figure 4 Histological assessment of TRAMP-C2 prostate tumors. (A) Composite images and magnified images of H&E-stained sections indicating necrotic regions. (B, C)
RGB images from tumor sections stained with (B) CD4 (red) and CD8 (green), and (C) CD3 (red) and NK1.1 (green) antibodies. Nuclei were stained with DAPI (blue).
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Cyto-IL-15 Treatment Leads to Significant
Changes in Gene Expression in Prostate
Subcutaneous Tumors
To investigate whether cyto-IL-15 treatment had an impact
on gene expression, a comparison of genes was performed
between tumors treated with vehicle, IL-15 or cyto-IL-15.
Genes with an adjusted p-value <0.05 and absolute log2
fold change >1 were considered as differentially expressed
genes. When vehicle-treated tumors were compared with
IL-15-treated tumors only eight genes were differentially
expressed (3 upregulated and 5 downregulated). However,
when vehicle and cyto-IL-15 cohorts were compared, a total
of 1130 genes were significantly differentially expressed
(866 upregulated and 264 downregulated). Similarly, 1095
genes were differentially expressed (869 upregulated and
226 downregulated) when tumors from the IL-15 and cyto-
IL-15 cohorts were compared. A list of all the differentially
expressed genes in all three comparison sets is provided in























































































































Figure 5 Quantification of necrotic area and immune cell infiltration in TRAMP-C2 tumors. (A) Necrotic area. Results are means +1 SEM of two sections per tumor for all
tumors. (B) CD4 positive-stained area, (C) CD8 positive area, (D) CD3 positive area, and (E) NK1.1 positive-stained area. Results are means +1 SEM of 10 images per
tumor for n = 5 per group. Comparisons are relative to vehicle unless otherwise indicated (*p <0.05, **p <0.01, ***p <0.001, ****p <0.0001 one-way ANOVA with Dunnett’s
multiple comparisons post-test).
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Table S2 (Supplementary File). Figure 6A shows heatmaps
of the top 30 differentially expressed genes (8 genes in the
case of vehicle versus IL-15). While IL-15 treatment caused
very few, almost negligible, changes in gene expression
compared with vehicle, cyto-IL-15 led to dramatic gene
expression changes compared with vehicle or IL-15. More
than 1000 genes, including Sema3e, Wnt4, Pdcd4, Bbip1,
Yap1, Shoc2, Lamp3, Ndn, Fst, Erfe, Krt80 and Gabra3,
were differentially expressed in both comparisons. The
gene ontology analysis showed that the differentially
expressed genes in both vehicle versus cyto- IL-15 and
IL-15 versus cyto-IL-15 comparisons were involved in
processes such as cell adhesion, cell proliferation, cell
migration and axon guidance (Figure 6B). In the compar-
ison of IL-15 versus cyto-IL-15, several differentially
expressed genes were also involved in angiogenesis.
The protein expression levels of one of the most upre-
gulated genes, Pdcd4, were also investigated in tumor
homogenates from mice treated with either vehicle, IL-15
or cyto-IL-15 using Western blot analysis (Supplementary
Methods: SDS-PAGE electrophoresis and Western blot
analysis, Supplementary File). A significantly higher
Pdcd4 protein expression (p <0.05) was seen in the cyto-
IL-15-treated tumors compared both with vehicle or IL-
15-treated tumors (Figure S7, Supplementary File).
Discussion
In the present study, novel membrane-localising forms of
IL-15, and CTLA-4 and PD-L1 antibodies were engi-
neered to enable them to anchor to cell membranes. The
efficacy of these agents was investigated in a prostate
cancer murine model. Our key findings indicate that
cyto-IL-15 or cyto-combo significantly prolonged mouse
survival by delaying tumor growth and inducing necrosis,
without any side effects. The observed necrosis was asso-
ciated with enhanced recruitment and expansion of NK
and T cells in the tumors. Moreover, cyto-IL-15 had an
extensive impact on tumor gene expression compared with
its non-modified form.
The technology of cytotopically-modified agents has been
used previously to create a membrane-localizing form of the
human complement receptor type 1, Mirococept, for inhibit-
ing complement activation. Mirococept can prolong the sur-
vival of donor kidneys in rats and has been used to prevent
delayed graft function in a clinical trial of renal
transplantation.38,39 A membrane-localising hirudin-like
peptide, Thrombalexin 1, has also been developed and used
to inhibit thrombin and prevent acute antibody-mediated
thrombosis in donor organs in a rat model of hyperacute
rejection.33
In our study, treatment with cyto-IL-15 or a combina-
tion of cyto-IL-15 and cyto-antibodies led to both a sig-
nificant growth delay of TRAMP-C2 prostate tumors in
mice and an increase in survival compared with control.
This effect was greater than treatment with cyto-abs alone
or with non-localising forms of the same agents, as these
did not lead to significant differences compared with con-
trol, either in terms of tumor growth or in terms of mouse
survival. Antibodies or cyto-antibodies also have an effect
on either tumor growth or survival but this effect is more
delayed compared with the effect of cyto-IL-15 and cyto-
combo. For tumor growth, effects are observed mainly
from day 14 (day 10 for cyto-combo); however, for cyto-
abs, changes are only visible on day 17. This delayed
action of the checkpoint inhibitor antibodies can be
explained by the different mechanism of killing cancer
cells compared to IL-15. IL-15 leads to expansion and
activation of NK cells and the generation of CD8 cytotoxic
T lymphocytes.40 Activated NK cells release secretory
lysosomes containing cytotoxic proteins, such as gran-
zymes and perforin, that kill tumor cells, whereas CTLs
kill target cells by releasing granzymes A and B or by
induction of Fas ligand-mediated apoptosis. NK and CTLs
also exert antitumor effects by releasing IFN-γ and TNF-α.
However, activated T cells upregulate inhibitory check-
points such as CTLA-4 and PD-1, which in turn prevent
CD28 co-stimulation by competing for B7 binding and
interfere with T cell receptor signalling by binding to
PD-L1/PD-L2, respectively, leading eventually to abroga-
tion of the activated T cell response. Moreover, continuous
exposure to IFN-γ upregulates PD-L1 on cancer cells,
which in turn suppresses the proliferation and functions
of NK cells and CTLs, and induces T cell apoptosis.41–43
Blocking PD-L1 and CTLA-4 using checkpoint inhibitors,
such as the abs or cyto-abs used in our study, can relieve
the exhaustion of CD8 T cells and renew their priming,
and thereby further eliminate antigen-expressing tumor
cells. Hence, it appears that the antibodies reach their
full potential later on during treatment than IL-15, but
since most of the mice in the vehicle group reach the
maximum tumor size around day 17 it is difficult to
make comparisons after that point.
Overall, our findings are in agreement with a previous
study in TRAMP-C2 subcutaneous tumors showing that
Dovepress Papaevangelou et al
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Figure 6 Effects of cyto-IL15 treatment on gene expression in TRAMP-C2 tumors. Differential gene expression analysis followed by gene ontology analysis were performed
between tumors treated with vehicle or IL-15 (top panel), with vehicle or cyto-IL-15 (middle panel), and with IL-15 or cyto-IL-15 (bottom panel) (n = 3/cohort). (A) Bi-clustering
heatmaps of the log2 transformed expression values in each sample showing the expression profiles of the top 30 differentially expressed genes (all 8 differentially expressed genes
are shown in the vehicle versus IL-15 comparison). (B) Gene ontology (GO) enrichments of all significantly differentially expressed genes (adjusted p-value < 0.05) for each of the
three comparison sets. The numbers next to the bars indicate the number of significantly differentially expressed genes involved in each biological process.
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murine IL-15 treatment decreased tumor growth and pro-
longed mice survival and that these effects were augmented
when IL-15 was co-administrated together with anti-CTLA-
4 and anti-PD-L1 antibodies.30 However, to achieve this
level of efficacy, the mice received a higher total dose of
IL-15 (75 µg) and antibodies (600 µg each) compared to the
total dose in our study (20 µg for IL-15 and 100 µg for each
antibody). Another study in TRAMP-C2 tumors showed that
treatment with murine IL-15 combined with anti-CD40 anti-
body, which increased IL-15Rα expression on DCs, resulted
in more than 70% tumor remissions.44
In a clinical trial in patients with metastatic melanoma or
renal cell cancer, intravenously administered IL-15,
increased NK and CD8 T cell populations in circulating
blood, and cleared lung lesions in two patients; however, it
led to several dose-limiting toxicities, such as fever, hypoten-
sion and thrombocytopenia, which were associated with
inflammatory cytokine secretion.45 This study suggested
that to minimize toxicity and increase efficacy of IL-15
treatment, the maximum serum concentration of IL-15 and
excess cytokine release must be reduced, while optimal IL-
15 concentration is maintained for a longer period as free IL-
15 has a short half-life. One approach to extend the half-life
of free IL-15 and improve its efficacy was to use an IL-15
superagonist/IL-15Rα fusion complex (ALT-803) shown to
enhance the number and activity of NK and T cells.46 ALT-
803 was used in patients with hematologic malignancies who
relapse after allogeneic hematopoietic cell transplantation.
Despite ALT-803 beingwell tolerated, especially when admi-
nistered subcutaneously to avoid systemic toxicities,
responses were observed in less than 20% of the patients.47
Subcutaneous administration of IL-15 (without IL-15Rα)
was also well tolerated in patients with refractory solid
tumors and increased circulating NK and CD8 T cells,
although it led to no objective responses.48 Several studies,
reviewed by Marabelle et al,49 have shown that high concen-
trations of immunostimulating drugs in the blood can be
prevented by local injection leading to lower toxicities.
Intratumoral delivery of these agents allows higher concen-
trations in the tumor microenvironment than systemic infu-
sions, resulting in improved efficacy. However, there are
practical limitations if repeated injections are required to
trigger the adaptive immune response. In our study, we
enhanced the efficacy of IL-15 by injecting it in the tumor
microenvironment where cancer cells are in abundance while
minimizing toxicities (low serum concentrations). Moreover,
by tethering IL-15 to cell membranes we improved its
efficacy, with only two injections of the drug, potentially by
prolonging its retention in the tumor site.
The cyto-IL-15-mediated antitumor immune responses
seen in our study were likely due to expansion and recruit-
ment of NK, CD8 and CD4 T cells in the tumor micro-
environment, as showed by increased staining in
histological tumor sections. This is in agreement with
preclinical and clinical studies, which demonstrated that
after administration of recombinant (r)IL-15 or ALT-803,
the main mechanism attributing to the potential of IL-15 to
promote antitumor responses is the ability to prolong
expansion and activation of NK cells, CD8 memory T
cells and in some cases CD4 T cells.27,45,50,51 However,
response to IL-15 and subsequent activation of T cells
often results in increased production of pro-inflammatory
cytokines, known as cytokine release syndrome. This
usually involves an overproduction of IL-6, IL-10, TNF-
α and IFN-γ and can lead to detrimental effects in patients,
ranging from fever and heart problems to vascular leakage
and death.52 Treatment with ALT-803 resulted in marked
elevations of IFN-γ, TNF-α, and IL-10 in mice, but with-
out any toxicities.51 Administration of rIL-15 in patients
with malignant melanoma increased IL-6, IL-8, IFN-γ,
TNF-α and IL-1β levels, which coincided with acute clin-
ical toxicities, such as fever and blood pressure changes.45
In our study, when cytokines were measured in tumor
extracts at the experimental endpoint, IL-10, GM –CSF
and IFN-α were mildly elevated only in the non-modified
combination cohort, whereas IL-1β was increased in the
modified combination but without any toxicities (no
weight loss or development of rashes). No cytokine levels
were changed at the end of IL-15 monotherapy, suggesting
that if there were any changes during NK and T cell
activation, these changes were transient and did not
cause side effects.
When gene expression was investigated, we found that
cyto- IL-15 led to significant changes compared with
vehicle or non-modified IL-15. Among the most upregu-
lated genes was Sema3e (semaphorin-3e) with an approx-
imate 10-fold change in both comparisons. Sema3e is an
axon guidance molecule expressed by DCs that binds to
plexin-D1 expressed by NK cells. It has been suggested
that Sema3e production is involved in regulating NK cell
activation and functions, or in DC homeostasis in NK-DC
crosstalk.53 Another gene, and also protein expression,
upregulated by cyto-IL-15 was the tumor suppressor
gene programmed cell death protein 4 (Pdcd4) (~5 fold-
change), which is known to deregulate DNA-damage
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response and induce apoptosis in tumor cells.54,55 Most of
the differentially expressed genes in our study were
involved in processes such as cell adhesion, proliferation,
migration and angiogenesis (in the comparison of IL-15
versus cyto-IL-15). A previous study in a murine prostate
cancer model has also shown that IL-15 is involved in the
regulation of cell migration, proliferation, and blood vessel
formation.56 Moreover, RNA sequencing of IL-15 cyto-
kine-induced killer cells generated from PBMCs showed
upregulation of members of the Wnt signalling pathway
(especially Wnt4), which is known to be involved in cell-
cell adhesion, cell proliferation and differentiation.57
Similarly, in our study, several members of the Wnt family
(Wnt4, Wnt11 and Wnt7) were upregulated, and cell adhe-
sion and proliferation were the most significant GO terms.
Furthermore, a study has shown that IL-15 stimulates the
migratory response of NK cells by chemotaxis and
increases their adhesion to vascular endothelium, which
is the primary step for their extravasation and recruitment
to tissue.58 Hence, we can speculate that the effect of cyto-
IL-15 in upregulating genes involved in cell adhesion
observed in our study could also be part of the role of
IL-15 in augmenting NK cell adhesion and enabling their
recruitment to the tumor.
Conclusion
We have demonstrated that intratumor administration of the
cell membrane-anchoring IL-15, by providing a higher-loca-
lised effective dose and a potentially prolonged duration of
action, generated an effective immune response that led to
significant increases in both antitumor effect and survival of
tumor-bearing animals without any toxicities in a prostate
cancer model. Administration of IL-15 in combination with
blockade of CTLA-4 and PD-L1 led to similar effects, which
were slightly improved when the localisable forms of the
agents were used, but not superior to that of cyto-IL-15 alone.
A pharmacokinetic study to fully assess the intratumoral
half-life of the cytotopically modified IL-15 will have to be
performed in the future. However, this study provides the
scientific basis for clinical trials where cyto-IL-15 will be
used as a monotherapy administered directly into the tumors
of patients with prostate cancer or other solid tumors.
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